Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 2016

View Archived Issues

Researchers present phase Ib results on Lilly's taladegib for SCLC

Blueprint Medicines discloses preliminary first-in-human data of BLUE-285 in GIST patients

Ropeginterferon alfa-2b shows promise in patients with polycythemia vera

Investigators present phase II results on CTL-019 in ALL patients

Ascendance Biotechnology gains rights to GE Healthcare's Cytiva cardiomyocytes

Achillion Pharmaceuticals receives milestone payment for JNJ-4178

Vertex Pharmaceuticals patents triazoles for demyelinating diseases

Medshine Discovery discloses JAK inhibitors

Galena Biopharma gives update on regulatory plans for GALE-401

Syros Pharmaceuticals describes c-Myc inhibitors

Dana-Farber Cancer Institute develops SMO receptor antagonists

Chiesi Farmaceutici presents muscarinic M3 receptor antagonists and beta2-adrenoceptor agonists

Patient enrollment begins in phase I trial of TQ-B3395 in patients with advanced cancer

EMT gene expression as biomarkers in neuroendocrine lung carcinoma

Shire is enrolling patients in phase III trial of maribavir in transplant recipients

Bristol-Myers Squibb initiates phase II trial of BMS-986165

AstraZeneca initiates phase I trial of AZD-0284 for plaque psoriasis

AstraZeneca studies AZD-8871 for COPD in phase IIa trial

Lilly begins phase I study of LY-2775240

New phase II/III trial investigates Glassia for acute GvHD

Clovis initiates phase II trial of rucaparib for metastatic castration-resistant prostate cancer

Boehringer Ingelheim initiates phase I trial of BI-754091 in solid tumors

Lilly initiates first-in-human study of LY-3209590 for type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...